Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AXPH is funding a Phase II trial of a second generation tryptase inhibitor, APC 2059,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury